Thalia Therapeutics (THAT)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.57p
   
  • Change Today:
      0.008p
  • 52 Week High: 0.60
  • 52 Week Low: 0.57
  • Currency: UK Pounds
  • Shares Issued: 1,775.72m
  • Volume: 0
  • Market Cap: £10.06m

THAT Overview

We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Registrars: Capita Registrars

Key Personnel

CEO: David H Solomon
Executive Director: Luke Cairns
Independent Non-Executive Director: Alastair Smith
Non-Executive Chairman: Chris Britten
Non-Executive Dir: Michael Palfreyman, Edward Wardle

Contact Details

Address: 2 Portman Street, London, United Kingdom, W1H 6DU
Phone: +44 020 4610 0714
Website: http://www.thaliatx.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BYW8QM32

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

THAT Market Data

Currency UK Pounds
Share Price 0.57p
Change Today 0.008p
% Change -1.45 %
52 Week High 0.60
52 Week Low 0.57
Volume 0
Shares Issued 1,775.72m
Market Cap £10.06m

THAT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Value Not Available
Income Not Available
Growth Not Available

THAT Dividends

No dividends found

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

THAT Key Personnel

CEO David H Solomon

Top of Page